Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and
anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the
response rate of the combination and evaluate other clinical parameters such as
progression-free survival and safety of the combination following anti-PD1/L1 antibody. The
study will also provide the opportunity to investigate blood or tumor based factors that may
predict response to anti-PD1 antibody in combination with anti-CTLA4.